Gierse James, Nickols Maureen, Leahy Kathleen, Warner James, Zhang Yan, Cortes-Burgos Luz, Carter Jeffery, Seibert Karen, Masferrer Jaime
Pfizer Global Research and Development, 700 Chesterfield Village Parkway N., Chesterfield, Missouri 63198, United States.
Eur J Pharmacol. 2008 Jun 24;588(1):93-8. doi: 10.1016/j.ejphar.2008.03.057. Epub 2008 Apr 6.
A new class of selective cyclooxygenase-2 (COX-2) inhibitors has been identified by high throughput screening. Structurally distinct from previously described selective COX-2 inhibitors, these benzopyrans contain a carboxylic acid function and CF3 functionality. The compound SC-75,416 is a representative of this class. A range if in vitro and in vivo tests were employed to characterize its potency and selectivity. Using human recombinant enzymes, this compound displays a concentration that provides 50% inhibition (IC50) of 0.25 microM for COX-2 and 49.6 microM for COX-1. A mutation of the side pocket residues in COX-2 to COX-1 had little effect on potency suggesting that these inhibitors bind in a unique manner in COX-2 distinct from COX-2 inhibiting diaryl heterocycles. Using rheumatoid arthritic synovial cells stimulated with interleukin-1beta (IL-1beta) and washed platelets the compound displayed IC50 of 3 nM and 400 nM respectively. Potency and selectivity was maintained but predictably right shifted in whole blood with IC50 of 1.4 microM for lipopolysaccharide (LPS) stimulated induction of COX-2 and >200 microM for inhibition of platelet thromboxane production. SC-75,416 is 89% bioavailable and its in vivo half life is sufficient for once a day dosing. In the rat air pouch model of inflammation, the compound inhibited PGE2 production with an effective dose that provides 50% inhibition (ED50) of 0.4 mg/kg, while sparing gastric prostaglandin E2 (PGE2) production with an ED50 of 26.5 mg/kg. In a model of acute inflammation and pain caused by carrageenan injection into the rat paw, the compound reduced edema and hyperalgesia with ED50s of 2.7 and 4 mg/kg respectively. In a chronic model of arthritis the compound demonstrated an ED50 of 0.081 mg/kg and an ED(80) of 0.38 mg/kg. In a model of neuropathic pain, SC-75,416 had good efficacy. This compound's unique chemical structure and effect on COX enzyme binding and activity as well as its potency and selectivity may prove useful in treating pain and inflammation.
通过高通量筛选已鉴定出一类新型的选择性环氧化酶-2(COX-2)抑制剂。这些苯并吡喃在结构上与先前描述的选择性COX-2抑制剂不同,含有羧酸官能团和三氟甲基官能团。化合物SC-75416是这类抑制剂的代表。采用了一系列体外和体内试验来表征其效力和选择性。使用人重组酶时,该化合物对COX-2的半数抑制浓度(IC50)为0.25微摩尔,对COX-1的IC50为49.6微摩尔。COX-2侧袋残基突变为COX-1对效力影响不大,这表明这些抑制剂在COX-2中的结合方式独特,不同于抑制COX-2的二芳基杂环化合物。使用白细胞介素-1β(IL-1β)刺激的类风湿性关节炎滑膜细胞和洗涤过的血小板时,该化合物的IC50分别为3纳摩尔和400纳摩尔。在全血中,效力和选择性得以维持,但可预测地右移,脂多糖(LPS)刺激诱导COX-2的IC50为1.4微摩尔,抑制血小板血栓素生成的IC50大于200微摩尔。SC-75416的生物利用度为89%,其体内半衰期足以支持每日一次给药。在大鼠气囊炎症模型中,该化合物抑制前列腺素E2(PGE2)生成的有效剂量(ED50)为0.4毫克/千克,而对胃前列腺素E2(PGE2)生成的保护作用的ED50为26.5毫克/千克。在角叉菜胶注射大鼠足爪引起的急性炎症和疼痛模型中,该化合物分别以2.7毫克/千克和4毫克/千克的ED50减轻水肿和痛觉过敏。在慢性关节炎模型中,该化合物的ED50为0.081毫克/千克,ED80为0.38毫克/千克。在神经性疼痛模型中,SC-75416具有良好的疗效。该化合物独特的化学结构及其对COX酶结合和活性的影响,以及其效力和选择性,可能在治疗疼痛和炎症方面具有应用价值。